HbA1c Test Underestimates Glucose Control in Hemodialysis Patients
|
By Labmedica staff writers Posted on 25 Feb 2008 |
|
The standard hemoglobin A1c test (HbA1c) for estimating blood sugar control in people with diabetes is not accurate in those undergoing kidney hemodialysis.
HbA1c measures the percentage of hemoglobin (a protein in erythrocytes) that has reacted with glucose. This measure, also known as glycosylated hemoglobin, generally reflects blood sugar control over the previous 30-120 days.
A study, performed by researchers at Wake Forest University Baptist Medical Center (Winston-Salem, NC, USA), evaluated the HbA1c test 307 patients with diabetes, 258 with end-stage kidney disease on hemodialysis, and 49 who did not have kidney failure. The standard HbA1c test was compared with a newer test (glycated albumin [GA]), which measures the amount of blood sugar that has reacted with albumin, a protein in the plasma. The GA test reflects blood sugar control over the previous three to four weeks. Blood samples were also analyzed to determine recent blood sugar levels.
Compared to those without kidney failure, diabetic patients on hemodialysis had higher blood sugars and GA levels, despite lower HbA1c results. The relationship between GA and HbA1c differed between diabetic dialysis patients and those without kidney disease, indicating that the HbA1c did not accurately reflect blood sugar control in those on hemodialysis.
The major reason for the discrepancy appears to be that HbA1c depends on erythrocyte survival and these cells do not live as long in hemodialysis patients. Most dialysis patients have anemia requiring treatment with medications that stimulate erythrocyte production (erythropoietin).
Controlling blood sugar is important because high levels are risk factors for developing atherosclerosis and lead to higher rates of kidney disease, heart attack, stroke, nerve damage, and blindness. People with diabetes who undergo hemodialysis are especially at high risk. About one out of four diabetic dialysis patients (23%) in the United States will die from cardiovascular and infection complications during their first year on dialysis, and only 31% survive five years.
Related Links:
Wake Forest University Baptist Medical Center
.jpg)
HbA1c measures the percentage of hemoglobin (a protein in erythrocytes) that has reacted with glucose. This measure, also known as glycosylated hemoglobin, generally reflects blood sugar control over the previous 30-120 days.
A study, performed by researchers at Wake Forest University Baptist Medical Center (Winston-Salem, NC, USA), evaluated the HbA1c test 307 patients with diabetes, 258 with end-stage kidney disease on hemodialysis, and 49 who did not have kidney failure. The standard HbA1c test was compared with a newer test (glycated albumin [GA]), which measures the amount of blood sugar that has reacted with albumin, a protein in the plasma. The GA test reflects blood sugar control over the previous three to four weeks. Blood samples were also analyzed to determine recent blood sugar levels.
Compared to those without kidney failure, diabetic patients on hemodialysis had higher blood sugars and GA levels, despite lower HbA1c results. The relationship between GA and HbA1c differed between diabetic dialysis patients and those without kidney disease, indicating that the HbA1c did not accurately reflect blood sugar control in those on hemodialysis.
The major reason for the discrepancy appears to be that HbA1c depends on erythrocyte survival and these cells do not live as long in hemodialysis patients. Most dialysis patients have anemia requiring treatment with medications that stimulate erythrocyte production (erythropoietin).
Controlling blood sugar is important because high levels are risk factors for developing atherosclerosis and lead to higher rates of kidney disease, heart attack, stroke, nerve damage, and blindness. People with diabetes who undergo hemodialysis are especially at high risk. About one out of four diabetic dialysis patients (23%) in the United States will die from cardiovascular and infection complications during their first year on dialysis, and only 31% survive five years.
Related Links:
Wake Forest University Baptist Medical Center
Gold Member
Troponin T QC
Troponin T Quality Control
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Vaginitis Test
Allplex Vaginitis Screening Assay
Latest Clinical Chem. News
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Channels
Molecular Diagnostics
view channel
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
